|
1 Indications And Usage Therapy With Lipid-Altering Agents Should Be One Component Of Multiple Risk Factor Intervention In Individuals Who Require Modifications Of Their Lipid Profile. Drug Therapy Is Recommended As An Adjunct To A Diet Restricted In Saturated Fat And Cholesterol Only When The Response To Diet And Other Non-Pharmacological Measures Has Been Inadequate. Altoprev ® Is An Hmg-Coa Reductase Inhibitor (Statin) Indicated As An Adjunctive Therapy To Diet To: • Reduce The Risk Of Mi, Revascularization Procedures, And Angina In Patients Without Chd, But With Multiple Risk Factors. ( 1.1 ) • Slow The Progression Of Coronary Atherosclerosis In Patients With Chd As Part Of A Treatment Strategy To Lower Total-C And Ldl-C. ( 1.1 ) • Reduce Elevated Total-C, Ldl-C, Apo B, And Tg Levels And Increase Hdl-C In Adult Patients With Primary Hyperlipidemia (Heterozygous Familial And Nonfamilial) And Mixed Dyslipidemia. ( 1.2 ) Limitations Of Use Altoprev ® Has Not Been Studied In Fredrickson Types I, Iii, And V Dyslipidemias. ( 1.3 ) 1.1 Prevention Of Coronary Heart Disease In Patients Without Symptomatic Coronary Heart Disease (Chd), But At High Risk, Altoprev ® Is Indicated To Reduce The Risk Of: • Myocardial Infarction • Unstable Angina • Coronary Revascularization Procedures Coronary Heart Disease Altoprev ® Is Indicated To Slow The Progression Of Coronary Atherosclerosis In Patients With Coronary Heart Disease As Part Of A Treatment Strategy To Lower Total-C And Ldl-C To Target Levels. 1.2 Hyperlipidemia Altoprev ® Is Indicated As An Adjunct To Diet For The Reduction Of Elevated Total-C, Ldl-C, Apo B, And Tg, And To Increase Hdl-C In Patients With Primary Hypercholesterolemia (Heterozygous Familial And Non-Familial) And Mixed Dyslipidemia (Fredrickson Types Iia And Iib). 1.3 Limitations Of Use Altoprev ® Has Not Been Studied In Fredrickson Types I, Iii, And V.
|